FDA approves pembrolizumab plus axitinib for advanced RCC
(HealthDay)—The combination of pembrolizumab and axitinib has been approved as a first-line treatment in advanced renal cell carcinoma (RCC), the […]
» Read moreHome »
FRIDAY, Oct. 26, 2018 — For patients with renal cell carcinoma (RCC), stereotactic ablative radiotherapy (SABR) seems to be as […]
ASTRO: Stereotactic Ablative RT OK for RCC in Solitary Kidneys
